# VIRUN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/virun

- Industry: Biotechnology
- Headquarters: Walnut, US
- Website: www.virun.com
- Total disclosed funding: $2.1M
- Latest round: Series A (Jul 15, 2012)
- Investors on record: 1

## About

Virun | Nutra Biosciences specializes in the formulation, manufacturing, and co-packing of dietary supplements and functional beverages, addressing challenges such as flavor enhancement and production scalability.Virun | Nutra Biosciences is a company focused on dietary supplement solutions, founded in 2003 in Walnut, California, US. The firm raised USD 2.10 mn in a Series A funding round on July 15, 2012, led by Bluestem Capital Company. The CEO of the company is Philip Bromley.Virun | Nutra Biosciences specializes in the formulation, manufacturing, and co-packing of dietary supplements and functional beverages. The company’s offerings aim to solve challenges in the health supplement sector, focusing on flavor enhancement, product stability, and scalability. With over 100 patents, Virun employs advanced technologies to produce high-quality, bioavailable products tailored for health-conscious consumers. Their services cater to a wide array of clients, including small to medium-sized enterprises, and they operate on an international scale, reaching markets in North America, Europe, and parts of Asia.Virun | Nutra Biosciences generates revenue through a multifaceted structure, including B2B partnerships and direct sales. The company engages clients through contracts for product formulation and manufacturing, ensuring a consistent flow of transactional agreements. Their pricing reflects the complexity and scale of client projects, with flagship products and proprietary technologies often commanding premium pricing.Virun | Nutra Biosciences plans to innovate new products that address specific health challenges, with upcoming launches anticipated in the near future. The company aims to expand into additional international markets, targeting Europe and Asia by 2025. The recent funding of USD 2.10 mn from the Series A round in July 2012 will support these expansion initiatives and product development efforts.

## Funding rounds

- Series A, Jul 15, 2012, $2.1M — Bluestem Capital Company

## Investors

- Bluestem Capital Company (https://capitalatlas.ai/funds/bluestem-capital-company) — Series A